🇺🇸 FDA

Company profile · Sponsor

CATALYST

CATALYST PHARMACEUTICALS, INC.

CPRX · NYSE pharma CORAL GABLES, FL, USA
Pipeline
23
Drugs
3
Patents
8

Quick answer

CATALYST (CPRX) is a pharma company. headquartered in CORAL GABLES, FL, USA. listed on NYSE. NovaPharmaNews links 23 pipeline programs, 3 drugs, and 8 patents to this profile..

Company facts

Ticker CPRX
Exchange NYSE
Company type pharma
Headquarters CORAL GABLES, FL, USA
SEC CIK 0001369568

Pipeline (23)

Search pipeline →

  1. Amifampridine Phosphate

    CATALYST

    Myasthenia Gravis, Generalized

    phase 3 small molecule completed

    1 trial

  2. Amifampridine Phosphate

    CATALYST

    Myasthenia Gravis, MuSK

    phase 3 small molecule terminated

    1 trial

  3. Amifampridine Phosphate

    CATALYST

    Lambert Eaton Myasthenic Syndrome

    phase 3 small molecule completed

    2 trials

  4. BT-001

    CATALYST

    Type2 Diabetes

    phase 3 other terminated

    1 trial

  5. MarzAA

    CATALYST

    Hemophilia A With Inhibitor

    phase 3 mab terminated

    1 trial

  6. amifampridine phosphate

    CATALYST

    Myasthenic Syndromes, Congenital

    phase 3 small molecule completed

    1 trial

  7. Amifampridine Phosphate

    CATALYST

    Muscular Atrophy, Spinal

    phase 2 small molecule completed

    1 trial

  8. Amifampridine Phosphate 10 MG Oral Tablet

    CATALYST

    Spinal Muscular Atrophy Type 3

    phase 2 small molecule terminated

    1 trial

  9. CPP-109 vigabatrin

    CATALYST

    Methamphetamine Dependence

    phase 2 small molecule terminated

    1 trial

  10. Coagulation Factor IX variant

    CATALYST

    Hemophilia B

    phase 2 mab completed

    1 trial

  11. Coagulation Factor VIIa variant

    CATALYST

    Hemophilia A With Inhibitor

    phase 2 mab completed

    1 trial

  12. Coagulation Factor VIIa variant

    CATALYST

    Factor VII Deficiency

    phase 2 mab terminated

    1 trial

  13. Decitabine

    CATALYST

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  14. Dupilumab

    CATALYST

    COVID-19

    phase 2 mab completed

    1 trial

  15. MHS-1031

    CATALYST

    Gastroesophageal Reflux

    phase 2 small molecule active

    1 trial

  16. vigabatrin

    CATALYST

    Cocaine Dependence

    phase 2 small molecule completed

    2 trials

  17. Airway Bypass

    CATALYST

    Emphysema or COPD

    phase 1 other active

    1 trial

  18. Bumetanide

    CATALYST

    Seizures

    phase 1 small molecule completed

    1 trial

  19. CPP-115

    CATALYST

    Cocaine Dependency

    phase 1 small molecule completed

    1 trial

  20. HWK-016, MUCIN-16-targeted ADC

    CATALYST

    PROC

    phase 1 small molecule active

    1 trial

  21. ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg

    CATALYST

    Hemophilia B

    phase 1 mab completed

    1 trial

  22. MarzAA (marzeptacog alfa [activated])

    CATALYST

    Hemophilia A

    phase 1 mab completed

    1 trial

  23. PF-05280602

    CATALYST

    Hemophilia A

    phase 1 mab completed

    1 trial

Drugs (3)

Search drugs →

  1. amifampridine phosphate

    FIRDAPSE

    ORAL approved

  2. perampanel

    FYCOMPA

    ORAL approved

    N03AX22

  3. vamorolone

    AGAMREE

    ORAL approved

    H02AB18

Patents (8)

Search patents →

  1. US 11806421

    Porous-cellulose particles and production method thereof, and cosmetic

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11701307

    Organic-inorganic composite particles, manufacturing method therefor, and cosmetic

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11491212

    Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11401513

    Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11384062

    Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11266724

    Modified factor VII polypeptides for subcutaneous administration and on-demand treatment

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11203749

    Factor VII polypeptides that are modified and uses thereof

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11020326

    Hollow particles and cosmetic

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is CATALYST?

CATALYST (CPRX) is a pharma company. headquartered in CORAL GABLES, FL, USA. listed on NYSE. NovaPharmaNews links 23 pipeline programs, 3 drugs, and 8 patents to this profile..

What pipeline programs does CATALYST sponsor?

We track 23 ClinicalTrials.gov-linked programs for CATALYST, including Amifampridine Phosphate and 22 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does CATALYST company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.